Even though the primary outcome was inconclusive, the encouraging results of the BICAR-ICU study by Jaber and colleagues 1 on the renal secondary outcomes provide some interesting arguments in the debate about the fluids content used in intensive care.
The beneficial effect of bicarbonate is notably explained by the authors by a decrease in the need for vasopressors. However, we think that the effect could also be linked, in the intervention group, to a lower chloride load with beneficial effects on renal dysfunction. Some experimental studies 2 indeed suggest an association between the chloride input and kidney injuries, in particular through a vasoconstriction of afferent arterioles, causing a decrease in the renal blood flow velocity and pro-inflammatory effects. These observations have also been noted in clinical studies, 3, 4 with, in the study by Shaw and colleagues, 4 a positive effect on mortality.
In the study by Jaber and colleagues, 1 several points remain unclear, even in light of table S2 and figure S5 in the appendix. 1 First, during the first 24 h, the cumulative fluid intake did not differ between the two groups, contrary to the cumulative sodium bicarbonate volume. This finding might result from a qualitative difference in the infused fluids composition, especially concerning chloride input. Moreover, because of the scarcity of intermediate identification of chloremia between enrolment and the 24th hour, some fluctuations might have been unnoticed.
Thus, a difference in the chloride load could explain, at least partly, the lower need for renal replacement therapy (especially in the subgroup with pre-existing acute kidney injury) as well as a mortality benefit.
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Authors' reply
We report 1 that in a severely acidaemic critically ill population, the infusion of 4·2% sodium bicarbonate solution to target a plasma pH equal or above 7·30 is not associated with a decrease in 28-day mortality and the presence of at least one organ failure at day 7 (primary composite outcome). One possible reason, as suggested by Cristian Baicus, is the insufficient power, 28-day mortality being decreased in the sodium bicarbonate group only after multivariate analysis. Interestingly and contrary to what was suggested by Sheldon Magder and Gordan Samoukovic, our trial also shows that sodium bicarbonate infusion is associated with a better 28-day mortality in the prespecified stratum of patients with moderate to severe acute kidney injury.
Whether the sodium bicarbonate infu sion was associated with a reduction in the number of long-term major kidney events is uncertain because data on long-term kidney function were not collected. However, the composite of death and new receipt of renal-replacement therapy during the intensive care unit stay in the overall population was 136 (70%) in the control group and 119 (61%) in the bicarbonate group (p=0·0596).
In our trial, most of the patients presented with hyperlactatemia, and gastrointestinal or kidney loss of bicarbonate were considered as exclusion criteria. Thibaut Baudic and colleagues asked whether a lower chloride load in the sodium bicarbonate group could have been an important mechanism associated with the better outcome observed in the bicarbonate group. Although no definitive answer could be given by this pragmatic trial, chloremia upon enrolment and at 24 h and 48 h was not different between the two groups (appendix figure S5) . 1 Finally, we absolutely agree with Magder and Samoukovic that our multicentre, randomised trial suggests for the first time that, although widely accepted, 2,3 severe acidaemia per se might be controlled by sodium bicarbonate infusion along with its mechanism-specific treatments, rather than being a reflex indication for dialysis. More studies certainly need to be done to better assess this hypothesis in the critically ill population presenting with moderate to severe acute kidney injury and severe acidaemia. that female graduates would quit working as full-time employees because of marriage, pregnancy, and childcare. To dispel concerns that similar discrimination might be prevalent in other medical schools, the Government initiated a nationwide investigation and revealed that many medical schools similarly restrict female student admission. In Japan, the majority of hospitals do not support flexible ways of working, and often present female doctors with tough choices during their careers, with a working environment that poses difficulties in balancing work and family life. In 2012, the proportion of unmarried female doctors aged 50 years was 35·9%, compared with 2·8% of male physi cians and 14·7% of the general female population. 3 Furthermore, the deep-rooted issue of sexual harassment is an inherent problem of Japanese society, as shown by the 114th placement of Japan among 144 nations in the Global Gender Gap report of 2017. 4 Notably, reports in the USA showed that treatment from female doctors resulted in better mortality rates compared with their male counterparts, 5,6 and medical practice by female doctors resulted in lower average total Medicare payments and fewer unique beneficiary visits than male doctors, irrespective of specialty types and years in practice. 5 Although it remains to be seen whether the same trends exist in the Japanese health-care system, recognition that female doctors practice medicine differently from male doctors would result in great improvements of the quality of health care in Japan.
Misogyny at the entrance exami nation of medical schools emphasises a social problem faced by women in Japan. To eliminate sexual harassment, it is time to introduce flexible ways of working to utilise the capabilities of female physicians rather than suppressing the number accepted into medical schools.
